Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Reversible Covalent Immune Recruiters: potent catalytic immunotherapeutics and chemical tools for probing engineered T cell receptor pharmacology
EF 2023-24
Résumé
Cancer immunotherapies are treatments that use a patient’s immune system to fight cancer. One method of cancer immunotherapy uses immune cells called T cells that have been engineered to attack cancer cells. Engineering T cells for each individual patient is a costly process. Additionally, cancer is a dynamic disease that can change and evade the engineered T cells. Previous work in the Rullo and Bramson labs developed universal T cells that target a small molecule instead of directly targeting cancer. A molecule that acts like a “glue”, bringing the universal T cell to a cancer target of choice, can then be used with the T cell as an immunotherapy. These glues can be swapped to target different cancer types as the disease evolves during the course of treatment. This project involves the development of molecular “glues” that bind to universal T cells reversibly. By varying the structure of the “glue”, the “stickiness” of the molecule to the T cell can be finely tuned. These molecules can reveal the optimal strength of a T cell-cancer cell interaction, and show how engineered T cells identify and kill their targets. Additionally, the reversibly binding “glues” show large improvements in efficacy over irreversibly binding “glues”, likely due to their ability to engage different T cells and targets multiple times during the cancer killing process. Reversible “glues” show promise as both effective immunotherapies and as chemical tools to probe how engineered T cells work.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506044
Name
Frankovich Tomas V
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Reversible Covalent Immune Recruiters: potent catalytic immunotherapeutics and chemical tools for probing engineered T cell receptor pharmacology
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cancer Immunotherapy; Chemical Biology; Covalent; Immunotherapy; Kinetic Proofreading; Molecular Glue; Receptor Pharmacology; T Cell
Abstract
Cancer immunotherapies are treatments that use a patient’s immune system to fight cancer. One method of cancer immunotherapy uses immune cells called T cells that have been engineered to attack cancer cells. Engineering T cells for each individual patient is a costly process. Additionally, cancer is a dynamic disease that can change and evade the engineered T cells. Previous work in the Rullo and Bramson labs developed universal T cells that target a small molecule instead of directly targeting cancer. A molecule that acts like a “glue”, bringing the universal T cell to a cancer target of choice, can then be used with the T cell as an immunotherapy. These glues can be swapped to target different cancer types as the disease evolves during the course of treatment. This project involves the development of molecular “glues” that bind to universal T cells reversibly. By varying the structure of the “glue”, the “stickiness” of the molecule to the T cell can be finely tuned. These molecules can reveal the optimal strength of a T cell-cancer cell interaction, and show how engineered T cells identify and kill their targets. Additionally, the reversibly binding “glues” show large improvements in efficacy over irreversibly binding “glues”, likely due to their ability to engage different T cells and targets multiple times during the cancer killing process. Reversible “glues” show promise as both effective immunotherapies and as chemical tools to probe how engineered T cells work.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Frankovich, Tomas V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~